TY - JOUR
T1 - Practical Guide on the Use of Induction Immunosuppression in Heart Transplantation
AU - Nikolova, Andriana P.
AU - Bellumkonda, Lavanya
AU - Bhardwaj, Anju
AU - Fida, Nadia
AU - Holzhauser, Luise
AU - Umapathi, Priya
AU - De Marco, Teresa
AU - Contreras, Johanna
N1 - Publisher Copyright:
© 2025 American Heart Association, Inc.
PY - 2025
Y1 - 2025
N2 - Induction therapy is the use of potent immunosuppression in the perioperative period with the intent to diminish rejection rates in at-risk patients or as a renal-protective strategy. The potent immunomodulatory effects of these agents must be balanced against the recipient's risk of infectious or malignant complications, among others. There is a notable lack of clinically useful risk stratification models that integrate these competing risks and guide the clinician in the use of these therapies. This review integrates the existing evidence on the utility and safety of various induction regimens and highlights the gaps of knowledge in the field. In addition, we frame the discussion in view of the changing landscape of heart transplantation where many unknowns remain, such as the impact of induction immunosuppression on patients bridged with mechanical circulatory devices or receiving organs from hepatitis C-positive or donation after circulatory death donors, among others.
AB - Induction therapy is the use of potent immunosuppression in the perioperative period with the intent to diminish rejection rates in at-risk patients or as a renal-protective strategy. The potent immunomodulatory effects of these agents must be balanced against the recipient's risk of infectious or malignant complications, among others. There is a notable lack of clinically useful risk stratification models that integrate these competing risks and guide the clinician in the use of these therapies. This review integrates the existing evidence on the utility and safety of various induction regimens and highlights the gaps of knowledge in the field. In addition, we frame the discussion in view of the changing landscape of heart transplantation where many unknowns remain, such as the impact of induction immunosuppression on patients bridged with mechanical circulatory devices or receiving organs from hepatitis C-positive or donation after circulatory death donors, among others.
KW - allografts
KW - cyclosporine
KW - heart transplantation
KW - immunosuppression therapy
KW - interleukin
UR - http://www.scopus.com/inward/record.url?scp=105005176097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105005176097&partnerID=8YFLogxK
U2 - 10.1161/CIRCHEARTFAILURE.124.012382
DO - 10.1161/CIRCHEARTFAILURE.124.012382
M3 - Review article
AN - SCOPUS:105005176097
SN - 1941-3289
JO - Circulation: Heart Failure
JF - Circulation: Heart Failure
M1 - e012382
ER -